UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Department of Social Medicine, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, SP, Brazil.
Reprod Health. 2018 Jan 30;15(1):16. doi: 10.1186/s12978-017-0437-8.
Maternal sepsis is the underlying cause of 11% of all maternal deaths and a significant contributor to many deaths attributed to other underlying conditions. The effective prevention, early identification and adequate management of maternal and neonatal infections and sepsis can contribute to reducing the burden of infection as an underlying and contributing cause of morbidity and mortality. The objectives of the Global Maternal Sepsis Study (GLOSS) include: the development and validation of identification criteria for possible severe maternal infection and maternal sepsis; assessment of the frequency of use of a core set of practices recommended for prevention, early identification and management of maternal sepsis; further understanding of mother-to-child transmission of bacterial infection; assessment of the level of awareness about maternal and neonatal sepsis among health care providers; and establishment of a network of health care facilities to implement quality improvement strategies for better identification and management of maternal and early neonatal sepsis.
This is a facility-based, prospective, one-week inception cohort study. This study will be implemented in health care facilities located in pre-specified geographical areas of participating countries across the WHO regions of Africa, Americas, Eastern Mediterranean, Europe, South East Asia, and Western Pacific. During a seven-day period, all women admitted to or already hospitalised in participating facilities with suspected or confirmed infection during any stage of pregnancy through the 42nd day after abortion or childbirth will be included in the study. Included women will be followed during their stay in the facilities until hospital discharge, death or transfer to another health facility. The maximum intra-hospital follow-up period will be 42 days.
GLOSS will provide a set of actionable criteria for identification of women with possible severe maternal infection and maternal sepsis. This study will provide data on the frequency of maternal sepsis and uptake of effective diagnostic and therapeutic interventions in obstetrics in different hospitals and countries. We will also be able to explore links between interventions and maternal and perinatal outcomes and identify priority areas for action.
产妇脓毒症是导致所有产妇死亡的 11%的根本原因,也是许多归因于其他根本原因的死亡的重要因素。有效预防、早期识别和充分管理产妇和新生儿感染及脓毒症,有助于降低感染作为发病和死亡的根本和促成因素的负担。全球产妇脓毒症研究(GLOSS)的目标包括:制定和验证用于识别可能严重产妇感染和产妇脓毒症的标准;评估推荐用于预防、早期识别和管理产妇脓毒症的核心实践的使用频率;进一步了解母婴间细菌感染的传播;评估卫生保健提供者对产妇和新生儿脓毒症的认识水平;建立一个卫生保健机构网络,实施质量改进策略,以更好地识别和管理产妇和早期新生儿脓毒症。
这是一项基于机构的、前瞻性的、为期一周的初始队列研究。本研究将在卫生保健机构中进行,这些机构位于参与国家的指定地理区域内,覆盖世界卫生组织非洲、美洲、东地中海、欧洲、东南亚和西太平洋区域。在为期七天的时间内,所有在参与机构中因疑似或确诊感染而住院或已经住院的、在妊娠任何阶段(流产或分娩后第 42 天)的妇女,包括有或没有严重脓毒症的妇女,都将被纳入研究。纳入的妇女将在机构内接受治疗,直至出院、死亡或转至另一家卫生机构。院内最长随访期为 42 天。
GLOSS 将为识别可能患有严重产妇感染和产妇脓毒症的妇女提供一套可操作的标准。本研究将提供不同医院和国家产妇脓毒症的频率和有效诊断及治疗干预措施的应用数据。我们还将能够探索干预措施与产妇和围产期结局之间的联系,并确定优先行动领域。